Form 4: Myriad Genetics CFO Awarded Performance Shares

Myriad Genetics' Chief Financial Officer, Benjamin Richard Wheeler, acquired 4,994 shares of common stock through a performance-based restricted stock unit award.

Summary

• Benjamin Richard Wheeler, Chief Financial Officer of Myriad Genetics Inc. (MYGN), acquired 4,994 shares of common stock.
• The acquisition occurred on February 2, 2026, at a price of $0 per share.
• These shares are performance-based restricted stock units (PSUs) initially granted on March 15, 2023.
• The final award amount was determined by the Compensation and Human Capital Committee on February 2, 2026, based on the accomplishment of pre-determined performance metrics.
• Each PSU represents a contingent right to receive one share of the Company's common stock.
• The PSUs are scheduled to vest on March 15, 2026.
• Following this transaction, Benjamin Richard Wheeler beneficially owns 97,624 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting the achievement of internal performance goals and strong alignment between executive compensation and company performance, which is generally favorable for shareholder confidence.

Positives

• The award of performance-based restricted stock units indicates that Myriad Genetics met its pre-determined performance metrics, reflecting positively on operational execution.
• The equity award aligns the Chief Financial Officer's interests with those of shareholders, incentivizing long-term value creation.

Future Outlook

The acquired performance-based restricted stock units are scheduled to vest on March 15, 2026, contingent on continued employment and other potential conditions.

Industry Context

StockSavvy.ai notes that performance-based equity awards are a common and effective incentive for executive compensation across the biotechnology and diagnostics industry, designed to align management's long-term interests with shareholder value creation.

Comparison to Industry Standards

• StockSavvy.ai notes that the use of performance-based restricted stock units for executive compensation is a standard practice within the biotechnology and healthcare sectors, comparable to compensation structures observed at companies like Illumina, Exact Sciences, or Guardant Health, which aim to link executive rewards directly to company performance and shareholder returns.

Stakeholder Impact

• Shareholders: The award of performance-based equity to the CFO reinforces alignment of management's incentives with shareholder value creation.
• Employees (CFO): Benjamin Richard Wheeler receives additional equity compensation, contingent on future vesting.

Next Steps

• The 4,994 performance-based restricted stock units are expected to vest on March 15, 2026.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled performance-based stock award to the CFO, indicating the achievement of internal metrics. It does not provide new fundamental information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

MYRIAD GENETICS, MYGN, Form 4, Insider Transaction, Stock Award, CFO, Benjamin Wheeler, Restricted Stock Units, PSU, Executive Compensation